| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PLA2G12 |
| Uniprot No | Q9BZM1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-185aa |
| 氨基酸序列 | QEQAQTTDWRATLKTIRNGVHKIDTYLNAALDLLGGEDGLCQYKCSDGSKPFPRYGYKPSPPNGCGSPLFGVHLNIGIPSLTKCCNQHDRCYETCGKSKNDCDEEFQYCLSKICRDVQKTLGLTQHVQACETTVELLFDSVIHLGCKPYLDSQRAACRCHYEE |
| 预测分子量 | 20.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PLA2G12重组蛋白的模拟参考文献示例(内容为虚构，仅供参考)：
---
1. **标题**: "Heterologous Expression and Functional Characterization of Recombinant Human PLA2G12 in Escherichia coli"
**作者**: Zhang L, et al.
**摘要**: 本研究成功在大肠杆菌中表达了重组人源PLA2G12蛋白，并通过亲和层析纯化获得高纯度产物。酶活性分析显示其具有特异性磷脂酶A2活性，且在体外模型中影响脂质代谢通路。
---
2. **标题**: "Structural Insights into PLA2G12: Crystallographic Analysis of a Recombinant Phospholipase A2 Group XII Protein"
**作者**: Tanaka K, et al.
**摘要**: 首次报道了重组PLA2G12的X射线晶体结构，揭示了其独特的催化活性位点和底物结合域，为理解其与其他PLA2亚型的功能差异提供了结构基础。
---
3. **标题**: "PLA2G12 Recombinant Protein Attenuates Hepatic Steatosis in a Mouse Model of Metabolic Dysfunction"
**作者**: Smith J, et al.
**摘要**: 利用哺乳动物细胞表达系统制备PLA2G12重组蛋白，动物实验表明其可通过调节脂蛋白分泌改善高脂饮食小鼠的肝脏脂肪变性，提示潜在治疗代谢疾病的应用。
---
4. **标题**: "Comparative Enzymatic Activity of PLA2G12 Recombinant Isoforms: Implications for Lipid Signaling"
**作者**: Chen R, et al.
**摘要**: 对比分析了不同重组PLA2G12异构体的酶动力学参数，发现其在不同pH和钙离子浓度下的活性差异，强调了其在细胞脂质信号传导中的调控多样性。
---
注：以上文献信息为模拟生成，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实文献。
PLA2G12 is a member of the phospholipase A2 (PLA2) superfamily, a group of enzymes that hydrolyze phospholipids at the *sn*-2 position to release free fatty acids and lysophospholipids. Specifically classified under the secreted PLA2 (sPLA2) subgroup, PLA2G12 is characterized by its unique structural and functional properties. Unlike many sPLA2s, PLA2G12 exhibits low enzymatic activity toward conventional phospholipid substrates, suggesting non-canonical roles beyond lipid metabolism. It is encoded by the *PLA2G12A* gene and is expressed in various tissues, including the liver, intestines, and immune cells.
Research highlights PLA2G12's involvement in lipid homeostasis and viral infection processes. Notably, it interacts with hepatitis C virus (HCV) particles, influencing viral assembly and infectivity, potentially through modulation of host lipid pathways. PLA2G12 has also been linked to lipoprotein metabolism, with studies in murine models showing altered plasma lipid profiles and reduced atherosclerosis upon its overexpression.
Recombinant PLA2G12 protein is produced using heterologous expression systems (e.g., *E. coli* or mammalian cells) for functional and structural studies. Its recombinant form retains the conserved sPLA2 features, including disulfide bonds and a calcium-binding loop critical for catalytic activity. However, its exact physiological substrates and mechanisms remain under investigation, partly due to its atypical enzymatic behavior.
Current interest in PLA2G12 revolves around its therapeutic potential. Inhibitors or enhancers of its activity could offer strategies for treating metabolic disorders, viral infections, or inflammatory diseases. Additionally, its role as a biomarker in certain pathologies is being explored. Despite progress, further studies are needed to fully elucidate its biological significance and translational applications.
×
